Lipoprotein oxidation biomarkers for cardiovascular risk: what does the future hold?

References

• Ravandi A, Boekholdt SM, Mallat Z et al. Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study. J. Lipid Res.52, 1829–1836 (2011).
   PubMed Web of Science ®Google Scholar
• Lewis MJ, Malik TH, Ehrenstein MR, Boyle JJ, Botto M, Haskard DO. Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation120, 417–426 (2009).
   PubMed Web of Science ®Google Scholar
• Miller YI, Choi SH, Wiesner P et al. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ. Res.108, 235–248 (2011).
   PubMed Web of Science ®Google Scholar
• Amir S, Hartvigsen K, Wagner O, Tsimikas S, Witztum JL, Binder CJ. Peptides isolated from a peptide phage display library mimic an epitope of MDA-LDL and apoptotic cells and are recognized by human autoantibodies. Circulation124, A16597 (2011).
   Google Scholar
• Hartvigsen K, Chou MY, Hansen LF et al. The role of innate immunity in atherogenesis. J. Lipid Res.50(Suppl.), S388–S393 (2009).
   PubMedGoogle Scholar
• Taleb A, Witztum JL, Tsimikas S. Oxidized phospholipids on apolipoprotein B-100 (OxPL/apoB) containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events. Biomarkers Med.5, 673–694 (2011).
   PubMed Web of Science ®Google Scholar
• Itabe H, Ueda M. Measurement of plasma oxidized low-density lipoprotein and its clinical implications. J. Atheroscler. Thromb.14, 1–11 (2007).
   PubMed Web of Science ®Google Scholar
• Rosenson RS. Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease. Cardiovasc. Drugs Ther.23, 93–101 (2009).
   PubMed Web of Science ®Google Scholar
• Kiechl S, Willeit J, Mayr M et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler. Thromb. Vasc. Biol.27, 1788–1795 (2007).
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Willeit P, Willeit J et al. Oxidation-specific biomarkers and prospective 15-year cardiovascular and stroke outcomes. J. Am. Coll. Cardiol. (2012) (Abstract).
   Google Scholar
• Tsimikas S, Mallat Z, Talmud PJ et al. Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. J. Am. Coll. Cardiol.56, 946–955 (2010).
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Brilakis ES, Miller ER et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N. Engl. J. Med.353, 46–57 (2005).
   PubMed Web of Science ®Google Scholar
• Raal FJ, Santos RD, Blom DJ et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet375, 998–1006 (2010).
   PubMed Web of Science ®Google Scholar
• Merki E, Graham M, Taleb A et al. Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. J. Am. Coll. Cardiol.57, 1611–1621 (2011).
   PubMed Web of Science ®Google Scholar
• Weismann D, Hartvigsen K, Lauer N et al. Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature478, 76–81 (2011).
   PubMed Web of Science ®Google Scholar
• Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA301, 2331–2339 (2009).
   PubMed Web of Science ®Google Scholar
• Clarke R, Peden JF, Hopewell JC et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N. Engl. J. Med.361, 2518–2528 (2009).
   PubMed Web of Science ®Google Scholar
• Davidson MH, Ballantyne CM, Jacobson TA et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J. Clin. Lipidol.5, 338–367 (2011).
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Chapman MJ, Ray K et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur. Heart J.31, 2844–2853 (2010).
   PubMed Web of Science ®Google Scholar
• Mallat Z, Lambeau G, Tedgui A. Lipoprotein-associated and secreted phospholipases A in cardiovascular disease: roles as biological effectors and biomarkers. Circulation122, 2183–2200 (2010).
   PubMed Web of Science ®Google Scholar
• Thompson A, Gao P, Orfei L et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet375, 1536–1544 (2010).
   PubMed Web of Science ®Google Scholar
• Ryu SK, Mallat Z, Benessiano J et al. Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes. Circulation125, 757–766 (2012).
   PubMedGoogle Scholar